Navigation Links
Cyprotex Launches Cloe(R) Gateway, its Secure web Portal for Access to Cyprotex Services Including an Enhanced Version of Cloe(R) PK.

MACCLESFIELD, England, May 7 /PRNewswire-FirstCall/ -- Cyprotex today (7th May 2009) launches Cloe(R) Gateway, a new secure web portal for access to drug discovery services. The initial offering via Cloe(R) Gateway is a new enhanced version of our proprietary predictive software, Cloe(R) PK, which predicts whole body pharmacokinetics from simple in vitro ADME and physicochemical properties.

Commenting on the launch, Dr Anthony D. Baxter, Cyprotex's Chief Executive Officer, said:

"I am delighted to announce the launch of our new and novel web portal Cloe(R) Gateway and its first product, an improved version of Cloe(R) PK. Cloe(R) PK, as a server based product, has been used by many of our customers for prediction of pharmacokinetic properties from early ADME data and found it to be very useful in decision making for candidate selection. Cyprotex have invested considerable time and effort improving the Cloe(R) PK model and we are proud to launch version 2.1 as an online service available via Cloe(R) Gateway. This will enable many more of our customers to utilise this excellent product on a simple pay-per-use model. The cost effectiveness of this approach will allow access of such predictive technologies to new audiences of scientists such as bench medicinal chemists. This approach to selling software solutions is new to the ADME / pharmacokinetic world and we anticipate it will grow to replace competitor products still being sold on the outdated server / license model.

The pharmaceutical industry has amassed a huge quantity of ADME data over the past few years and the availability of an online version of Cloe(R) PK though Cloe(R) Gateway will enable those companies to realise tremendous real added value from that data in the form of pharmacokinetic performance characteristics to enable faster, cheaper and better designed drugs to be developed.

I look forward to announcing further new products to be sold through Cloe(R) Gateway such as a human intestinal absorption model and a product to enable customers to access our largest selling product Cloe(R) Screen in the near future."

    For further information:
    Cyprotex PLC
    Helen Gill PhD, Product Development Manager
    Tel: +44(0)1625-505-100

SOURCE Cyprotex Discovery Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cyprotex Purchases Applied Biosystems Sciex QTRAP(R) 5500 LC-MS/MS
2. Cyprotex Introduces New Product Line Cloe(R) Select - a Portfolio of Bespoke ADME and PK Services
3. Tepha Partner Launches Novel Monofilament Absorbable Suture Utilizing Tephas Proprietary Biomaterial
4. Elsevier Launches Ten New eBook Specialty Collections on MD Consult
5. Histogen Aesthetics Launches ReGenica Rejuvenation System
6. AMG Launches EVOS fl, an 'Evolutionary' Fluorescence Microscope Based on Innovative EVOS Platform
7. GenVault Corporation Launches its Latest Centralized and Standardized Software Solution for Biobanking and Biological Sample Management, GenConnect 3.2
8. VisEn Launches Next-Generation Fast (Fluorescence Activatible Sensor Technology) Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo
9. Cell Biosciences Launches Next-Generation Protein Characterization System
10. Accera, Inc. Launches Neuera Pharmaceuticals, Inc.
11. ChemAxon Launches Marvin and JChem Version 5.2; Web Services, native .NET API, Homology Groups, 3D Alignment and Structural Frameworks
Post Your Comments:
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - ... "Company") announced today that the remaining 11,000 post-share ... Share Purchase Warrants (the "Series B Warrants") subject ... were exercised on November 23, 2015, which will ... Shares.  After giving effect to the issuance of ...
(Date:11/24/2015)... ... , ... InSphero AG, the leading supplier of easy-to-use solutions for production, culture, ... serve as Chief Operating Officer. , Having joined InSphero in November 2013 ... was promoted to Head of InSphero Diagnostics in 2014. There she has built ...
(Date:11/24/2015)... Capricor Therapeutics, Inc. (NASDAQ: ... development and commercialization of first-in-class therapeutics, today announced that ... scheduled to present at the 2015 Piper Jaffray Healthcare ... at The Lotte New York Palace Hotel in ... . --> . ...
(Date:11/24/2015)... MUNICH and NEW YORK , ... irst investment by Bristol-Myers Squibb in a ... Bristol-Myers Squibb Company in which the companies ... products in immuno-oncology and other areas of unmet medical need. ... Squibb in LSP 5, the latest LSP fund. This is ...
Breaking Biology Technology:
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... 29, 2015 Daon, a global leader in ... released a new version of its IdentityX Platform ... North America have already installed IdentityX v4.0 ... a FIDO UAF certified server component as ... activate FIDO features. These customers include some of the ...
(Date:10/29/2015)... , October 29, 2015 ... biometric authentication company focused on the growing mobile ... wallet announces that StackCommerce, a leading marketplace to ... featuring the Wocket® smart wallet on StackSocial for ... ) ("NXT-ID" or the "Company"), a biometric authentication ...
Breaking Biology News(10 mins):